美股新聞 標題聯播 · 近 24 小時 305 則 · 28 個來源 · 最新 9/20 06:00
本站只列標題、來源、時間與原文連結,不重製內文;著作權屬原媒體與原作者。新聞稿通路(PR Newswire、Business Wire、GlobeNewswire)是公司自己發的,屬第一手;媒體是轉述。
全部 · FATE近 30 天 4 則 · 第 1 / 1 頁
- Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026
- Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting
- Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference
- Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts
- Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis
- Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates
- Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
- Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Misses Revenue Estimates
- Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
- FATE Stock Jumps 6% As FDA Greenlights Moving Cell Therapy To Clinical Trials
- Sector Update: Healthcare Stocks Softer Late Afternoon
- Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate
- Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting
- Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences
- Fate Therapeutics Appoints Laura Hamill to Board of Directors
- H.C. Reiterates “Buy” Rating On Fate Therapeutics (FATE) With $7 PT
- Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting
- Fate Therapeutics Showcases Clinical Data for FT836 at the American Society of Cancer Oncology Annual Meeting
- Will Fate Therapeutics (NASDAQ:FATE) Spend Its Cash Wisely?
中文標題是機器翻譯(NLLB 模型,不外送資料),專有名詞靠對照表,語意以英文原題為準。預設藏掉:選股文與自動生成站(Motley Fool、24/7 Wall St、Trefis、MarketBeat…)、加密幣、律師事務所的股東訴訟廣告、非英文、新聞稿裡的人事任命 / 出席活動 / 得獎、個人理財專欄,以及通路稿標題對不到上市公司的。個股標籤是從標題辨識的(通路標準寫法 (NASDAQ: NVDA)、公司名對照);帶「?」的是從摘要辨識、信心較低。來源等級 A / B / C 只影響精選排序,不是對媒體的評價。